查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1859939

癌症基因治疗：全球市场占有率和排名、总销售额和需求预测（2025-2031 年）

Gene Therapies for Cancer Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 88 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年全球癌症基因治疗市场规模估计为82.3亿美元，预计到2031年将成长至304.9亿美元，2025年至2031年的复合年增长率为18.5%。

癌症基因疗法是一种创新治疗方法直接修改患者的基因组来治疗癌症。主要策略包括嵌合体抗原受体T细胞（CAR-T）疗法、CRISPR-Cas9等基因编辑技术、病毒载体介导的基因转殖。与传统的化疗和放射线治疗相比，基因疗法透过在分子层面上修復或替换癌基因、激活免疫系统识别并清除癌细胞或增强抗肿瘤免疫反应，具有更高的特异性和个人化治疗的优势。癌症基因疗法可应用于多种癌症类型，包括骨髓恶性肿瘤（例如白血病和淋巴瘤）和固态肿瘤（例如肺癌和乳癌）。儘管仍有高成本、生产过程复杂和长期疗效等挑战，但基因疗法在临床试验中展现的疗效使其成为肿瘤学领域的重要研究方向。

癌症基因治疗市场正因几个关键因素而快速发展。首先，癌症发生率的上升和传统治疗方法的限制推动了对新型治疗方案的需求。其次，基因编辑和细胞工程技术的进步使癌症基因疗法的研发和生产更具可行性。第三，支持个人化和精准医疗的监管政策为基因治疗的临床应用创造了有利环境。第四，人们对患者疗效和生活品质的日益关注推动了对创新治疗方法的需求。此外，生物製药公司与研究机构之间的合作正在加速技术转移和产品开发。

儘管癌症基因疗法潜力巨大，但仍有许多挑战和风险。首先，治疗费用高昂，涉及个人化细胞处理和基因编辑，对患者和医疗系统造成日益沉重的负担。其次，生产过程复杂，包括细胞采集、基因改造、扩增和再输注，任何偏差都可能影响疗效和安全性。第三，长期疗效和潜在副作用尚未完全阐明，需要更多临床数据进行检验。第四，监管核准流程繁琐耗时，可能延缓新型治疗方法的上市。第五，市场竞争激烈，许多公司和研究机构投入研发，增加了技术和产品同质化的风险。

癌症基因治疗的下游需求呈现以下趋势：首先，随着精准医疗概念的普及，患者和医疗机构对个人化治疗方案的需求日益增长。其次，随着疗效数据的积累，越来越多的患者开始考虑基因治疗，尤其是那些患有难治性或復发性癌症的患者。第三，保险公司和支付方正在逐步扩大基因治疗的承保范围，以减轻病患的经济负担。第四，由于患者对治疗安全性和生活品质的担忧，研发工作正致力于减少副作用和优化治疗方法。此外，病患教育和资讯撷取管道的改善也提高了患者对新型治疗方法的接受度。

本报告旨在按地区/国家、类型和应用对全球癌症基因治疗市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以收益为准，以2024年为基准年，对癌症基因治疗市场规模、估算和预测进行了阐述，并包含了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定癌症基因治疗业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Biogen
  • Novartis
  • Gilead Sciences
  • Sarepta Therapeutics
  • Sunway Biotech
  • SIBIONO
  • AnGes
  • Orchard Therapeutics
  • Human Stem Cells Institute

按类型分類的细分市场

  • 病毒载体
  • 非病毒载体

应用领域

  • 固态肿瘤
  • 骨髓恶性肿瘤

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Gene Therapies for Cancer Treatment was estimated to be worth US$ 8230 million in 2024 and is forecast to a readjusted size of US$ 30409 million by 2031 with a CAGR of 18.5% during the forecast period 2025-2031.

Cancer gene therapy is an innovative treatment approach that involves directly modifying the patient's genome to treat cancer. Common strategies include Chimeric Antigen Receptor T-cell (CAR-T) therapy, gene editing technologies such as CRISPR-Cas9, and viral vector-mediated gene transduction. Compared to traditional chemotherapy and radiotherapy, gene therapies offer higher specificity and personalized advantages by repairing or replacing oncogenes at the molecular level, activating the immune system to recognize and eliminate tumor cells, or enhancing anti-tumor immune responses. Cancer gene therapies are applicable to various cancer types, including hematologic malignancies (such as leukemia and lymphoma) and solid tumors (such as lung and breast cancer). Although challenges remain, such as high costs, manufacturing complexities, and long-term efficacy, the demonstrated effectiveness in clinical trials positions gene therapy as a significant research direction in oncology.

The cancer gene therapy market is rapidly evolving, driven by several key factors: First, the rising incidence of cancer and the limitations of traditional treatments have increased the demand for novel therapeutic options. Second, advancements in gene editing and cell engineering technologies have made the development and production of cancer gene therapies more feasible. Third, supportive policies from regulatory agencies regarding personalized and precision medicine have created a favorable environment for the clinical application of gene therapies. Fourth, patients' focus on efficacy and quality of life has driven the demand for innovative treatments. Additionally, collaborations between biopharmaceutical companies and research institutions have accelerated the translation of technologies and product development.

Despite the significant potential of cancer gene therapies, several challenges and risks persist. First, the high treatment costs, involving personalized cell processing and gene editing, increase the burden on patients and healthcare systems. Second, the manufacturing process is complex, encompassing cell collection, gene modification, expansion, and reinfusion, with any deviation potentially impacting efficacy and safety. Third, the long-term efficacy and potential side effects are not yet fully understood, requiring more clinical data for validation. Fourth, the regulatory approval processes are cumbersome and time-consuming, potentially delaying the market introduction of new therapies. Fifth, the market is highly competitive, with numerous companies and research institutions investing in R&D, leading to increased risks of technological and product homogeneity.

Downstream demand for cancer gene therapies is exhibiting the following trends: First, with the widespread adoption of precision medicine concepts, there is an increasing demand from patients and healthcare institutions for personalized treatment plans. Second, as efficacy data accumulates, more cancer patients, especially those with refractory or relapsed conditions, are considering gene therapies. Third, insurance companies and payers are gradually expanding coverage for gene therapies, reducing the financial burden on patients. Fourth, patients' concerns about treatment safety and quality of life are prompting research and development to focus more on controlling side effects and optimizing treatment regimens. Additionally, improvements in patient education and information access have enhanced acceptance of new therapies.

This report aims to provide a comprehensive presentation of the global market for Gene Therapies for Cancer Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Therapies for Cancer Treatment by region & country, by Type, and by Application.

The Gene Therapies for Cancer Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapies for Cancer Treatment.

Market Segmentation

By Company

  • Biogen
  • Novartis
  • Gilead Sciences
  • Sarepta Therapeutics
  • Sunway Biotech
  • SIBIONO
  • AnGes
  • Orchard Therapeutics
  • Human Stem Cells Institute

Segment by Type

  • Viral Vectors
  • Non-viral Vectors

Segment by Application

  • Solid Tumors
  • Hematologic Malignancies

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Gene Therapies for Cancer Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Gene Therapies for Cancer Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Gene Therapies for Cancer Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Gene Therapies for Cancer Treatment Product Introduction
  • 1.2 Global Gene Therapies for Cancer Treatment Market Size Forecast (2020-2031)
  • 1.3 Gene Therapies for Cancer Treatment Market Trends & Drivers
    • 1.3.1 Gene Therapies for Cancer Treatment Industry Trends
    • 1.3.2 Gene Therapies for Cancer Treatment Market Drivers & Opportunity
    • 1.3.3 Gene Therapies for Cancer Treatment Market Challenges
    • 1.3.4 Gene Therapies for Cancer Treatment Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Gene Therapies for Cancer Treatment Players Revenue Ranking (2024)
  • 2.2 Global Gene Therapies for Cancer Treatment Revenue by Company (2020-2025)
  • 2.3 Key Companies Gene Therapies for Cancer Treatment Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Gene Therapies for Cancer Treatment Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Gene Therapies for Cancer Treatment
  • 2.6 Gene Therapies for Cancer Treatment Market Competitive Analysis
    • 2.6.1 Gene Therapies for Cancer Treatment Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Gene Therapies for Cancer Treatment Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapies for Cancer Treatment as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Viral Vectors
    • 3.1.2 Non-viral Vectors
  • 3.2 Global Gene Therapies for Cancer Treatment Sales Value by Type
    • 3.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Type (2020-2031)
    • 3.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Solid Tumors
    • 4.1.2 Hematologic Malignancies
  • 4.2 Global Gene Therapies for Cancer Treatment Sales Value by Application
    • 4.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Application (2020-2031)
    • 4.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Gene Therapies for Cancer Treatment Sales Value by Region
    • 5.1.1 Global Gene Therapies for Cancer Treatment Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Gene Therapies for Cancer Treatment Sales Value by Region (2020-2025)
    • 5.1.3 Global Gene Therapies for Cancer Treatment Sales Value by Region (2026-2031)
    • 5.1.4 Global Gene Therapies for Cancer Treatment Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 5.2.2 North America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 5.3.2 Europe Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Gene Therapies for Cancer Treatment Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 5.5.2 South America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.3.2 United States Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.4.2 Europe Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.5.2 China Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.6.2 Japan Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.7.2 South Korea Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Gene Therapies for Cancer Treatment Sales Value, 2020-2031
    • 6.9.2 India Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Biogen
    • 7.1.1 Biogen Profile
    • 7.1.2 Biogen Main Business
    • 7.1.3 Biogen Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.1.4 Biogen Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Biogen Recent Developments
  • 7.2 Novartis
    • 7.2.1 Novartis Profile
    • 7.2.2 Novartis Main Business
    • 7.2.3 Novartis Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.2.4 Novartis Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Novartis Recent Developments
  • 7.3 Gilead Sciences
    • 7.3.1 Gilead Sciences Profile
    • 7.3.2 Gilead Sciences Main Business
    • 7.3.3 Gilead Sciences Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.3.4 Gilead Sciences Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Gilead Sciences Recent Developments
  • 7.4 Sarepta Therapeutics
    • 7.4.1 Sarepta Therapeutics Profile
    • 7.4.2 Sarepta Therapeutics Main Business
    • 7.4.3 Sarepta Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.4.4 Sarepta Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Sarepta Therapeutics Recent Developments
  • 7.5 Sunway Biotech
    • 7.5.1 Sunway Biotech Profile
    • 7.5.2 Sunway Biotech Main Business
    • 7.5.3 Sunway Biotech Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.5.4 Sunway Biotech Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Sunway Biotech Recent Developments
  • 7.6 SIBIONO
    • 7.6.1 SIBIONO Profile
    • 7.6.2 SIBIONO Main Business
    • 7.6.3 SIBIONO Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.6.4 SIBIONO Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.6.5 SIBIONO Recent Developments
  • 7.7 AnGes
    • 7.7.1 AnGes Profile
    • 7.7.2 AnGes Main Business
    • 7.7.3 AnGes Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.7.4 AnGes Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.7.5 AnGes Recent Developments
  • 7.8 Orchard Therapeutics
    • 7.8.1 Orchard Therapeutics Profile
    • 7.8.2 Orchard Therapeutics Main Business
    • 7.8.3 Orchard Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.8.4 Orchard Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Orchard Therapeutics Recent Developments
  • 7.9 Human Stem Cells Institute
    • 7.9.1 Human Stem Cells Institute Profile
    • 7.9.2 Human Stem Cells Institute Main Business
    • 7.9.3 Human Stem Cells Institute Gene Therapies for Cancer Treatment Products, Services and Solutions
    • 7.9.4 Human Stem Cells Institute Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Human Stem Cells Institute Recent Developments

8 Industry Chain Analysis

  • 8.1 Gene Therapies for Cancer Treatment Industrial Chain
  • 8.2 Gene Therapies for Cancer Treatment Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Gene Therapies for Cancer Treatment Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Gene Therapies for Cancer Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Gene Therapies for Cancer Treatment Market Trends
  • Table 2. Gene Therapies for Cancer Treatment Market Drivers & Opportunity
  • Table 3. Gene Therapies for Cancer Treatment Market Challenges
  • Table 4. Gene Therapies for Cancer Treatment Market Restraints
  • Table 5. Global Gene Therapies for Cancer Treatment Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Gene Therapies for Cancer Treatment Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Gene Therapies for Cancer Treatment Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Gene Therapies for Cancer Treatment Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Gene Therapies for Cancer Treatment
  • Table 10. Global Gene Therapies for Cancer Treatment Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapies for Cancer Treatment as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Gene Therapies for Cancer Treatment Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Gene Therapies for Cancer Treatment Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Gene Therapies for Cancer Treatment Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Gene Therapies for Cancer Treatment Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Gene Therapies for Cancer Treatment Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Gene Therapies for Cancer Treatment Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Gene Therapies for Cancer Treatment Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Gene Therapies for Cancer Treatment Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Gene Therapies for Cancer Treatment Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Gene Therapies for Cancer Treatment Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Gene Therapies for Cancer Treatment Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Gene Therapies for Cancer Treatment Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Gene Therapies for Cancer Treatment Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Gene Therapies for Cancer Treatment Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Gene Therapies for Cancer Treatment Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Biogen Basic Information List
  • Table 32. Biogen Description and Business Overview
  • Table 33. Biogen Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Biogen (2020-2025)
  • Table 35. Biogen Recent Developments
  • Table 36. Novartis Basic Information List
  • Table 37. Novartis Description and Business Overview
  • Table 38. Novartis Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Novartis (2020-2025)
  • Table 40. Novartis Recent Developments
  • Table 41. Gilead Sciences Basic Information List
  • Table 42. Gilead Sciences Description and Business Overview
  • Table 43. Gilead Sciences Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Gilead Sciences (2020-2025)
  • Table 45. Gilead Sciences Recent Developments
  • Table 46. Sarepta Therapeutics Basic Information List
  • Table 47. Sarepta Therapeutics Description and Business Overview
  • Table 48. Sarepta Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Sarepta Therapeutics (2020-2025)
  • Table 50. Sarepta Therapeutics Recent Developments
  • Table 51. Sunway Biotech Basic Information List
  • Table 52. Sunway Biotech Description and Business Overview
  • Table 53. Sunway Biotech Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Sunway Biotech (2020-2025)
  • Table 55. Sunway Biotech Recent Developments
  • Table 56. SIBIONO Basic Information List
  • Table 57. SIBIONO Description and Business Overview
  • Table 58. SIBIONO Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of SIBIONO (2020-2025)
  • Table 60. SIBIONO Recent Developments
  • Table 61. AnGes Basic Information List
  • Table 62. AnGes Description and Business Overview
  • Table 63. AnGes Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of AnGes (2020-2025)
  • Table 65. AnGes Recent Developments
  • Table 66. Orchard Therapeutics Basic Information List
  • Table 67. Orchard Therapeutics Description and Business Overview
  • Table 68. Orchard Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Orchard Therapeutics (2020-2025)
  • Table 70. Orchard Therapeutics Recent Developments
  • Table 71. Human Stem Cells Institute Basic Information List
  • Table 72. Human Stem Cells Institute Description and Business Overview
  • Table 73. Human Stem Cells Institute Gene Therapies for Cancer Treatment Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Gene Therapies for Cancer Treatment Business of Human Stem Cells Institute (2020-2025)
  • Table 75. Human Stem Cells Institute Recent Developments
  • Table 76. Key Raw Materials Lists
  • Table 77. Raw Materials Key Suppliers Lists
  • Table 78. Gene Therapies for Cancer Treatment Downstream Customers
  • Table 79. Gene Therapies for Cancer Treatment Distributors List
  • Table 80. Research Programs/Design for This Report
  • Table 81. Key Data Information from Secondary Sources
  • Table 82. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Gene Therapies for Cancer Treatment Product Picture
  • Figure 2. Global Gene Therapies for Cancer Treatment Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Gene Therapies for Cancer Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Gene Therapies for Cancer Treatment Report Years Considered
  • Figure 5. Global Gene Therapies for Cancer Treatment Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Gene Therapies for Cancer Treatment Revenue in 2024
  • Figure 7. Gene Therapies for Cancer Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Viral Vectors Picture
  • Figure 9. Non-viral Vectors Picture
  • Figure 10. Global Gene Therapies for Cancer Treatment Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Gene Therapies for Cancer Treatment Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Solid Tumors
  • Figure 13. Product Picture of Hematologic Malignancies
  • Figure 14. Global Gene Therapies for Cancer Treatment Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Gene Therapies for Cancer Treatment Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America Gene Therapies for Cancer Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Gene Therapies for Cancer Treatment Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value (%), (2020-2031)
  • Figure 27. United States Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India Gene Therapies for Cancer Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Gene Therapies for Cancer Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Gene Therapies for Cancer Treatment Industrial Chain
  • Figure 49. Gene Therapies for Cancer Treatment Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed